Late Acute Hematogenous Infections after Total Knee Arthroplasty: Results of Debridement, Antibiotics, and Implant Retention

全膝关节置换术后晚期急性血源性感染:清创、抗生素治疗和假体保留的疗效

阅读:2

Abstract

The frequency of late acute hematogenous infection (LAHI) following total knee arthroplasty (TKA) is between 0.2% and 0.5%. There is controversy over the results of patients treated for LAHIs by surgical debridement, antibiotics, and implant retention (DAIR). This narrative review of the literature aims to establish the role of DAIR in LAHIs after TKA. The published success rate (retention of the prosthesis) after DAIR is between 50% and 100%. The success rate is associated with a shorter duration of symptoms (5-14 days from the onset of symptoms). Factors associated with failure are an accompanying infection and the diagnosis of rheumatoid arthritis before the TKA is performed. It is not recommended to indicate a DAIR in patients with atrial fibrillation, chronic obstructive pulmonary disease, the presence of >15 cells per high-powered field, preoperative C-reactive protein >500 mg/L or methicillin-resistant S. aureus. In such patients, a two-stage revision arthroplasty should be recommended. Arthroscopic DAIR has a limited effect. It is most efficacious in the very early stage of acute presentations of infected TKA. It can be useful in patients with extreme frailty as an adjunct to suppressive antibiotic therapy. If carried out, high volumes of fluid should be utilized. The indications for an open DAIR are the following: duration of clinical signs and symptoms is less than 3 weeks; patients with a well-fixed implant; no abscess or sinus tract; low-virulence bacteria; elderly patients with multiple comorbidities; and nonimmunocompromised patients. Open DAIR should not be advised in cases with chronic infection (>4 weeks postoperatively, insidious beginning of symptoms).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。